EGFR and non-small cell lung carcinoma: Of note, a high degree of consensus (90.6%) was achieved on the clinically significant DFS benefit of osimertinib observed in the ADAURA study (statement 3), and on the fact that osimertinib could shift the treatment paradigm in patients with stage IB–IIIA EGFR-mutated NSCLC (71.9%) (statement 4).